Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-139

I share the general confusion about relating 15 kits to how many patients being dosed. And apparent lack of clarity about progress in other areas.
BP report 30 April does not share our confusion. Clearly states:

a) 15 infusion kits purchased. At least 5 patients
b) 10 transplant centres fully onboarded, 5 of which are treating patients
c) 10 more centres to onboard during June qtr
d) market access expanding. 37 states providing Medicaid now and remaining 41 states joining by 1 July
e) the team of 9 key account leaders commmenced activities in the lst week of April

BP reckons 5 patients uptake in the first month to market is outstanding. Cash receipts expected this qtr

BP gives the breakeven point for Ryoncil (wholesale access cost ~ US$1.55m / patient) at EBIT ~ 8 patients per qtr at current activity levels

BP goes on to say a lot about Revascor, with type B meeting in coming weeks, clarifying path to market***. Confirmation of meeting details will allow BLA preparation, possibly completed by December 2025. BLA approval potentially mid CY26

They describe the upcoming Type B meeting as a pivotal moment in the development of the drug. They say the market for Revascor is immense, estimating 6.5m patients affected by HF in the US every year, with thousands being added annually. MSB has made clear its intention to partner Revascor for HF. Partnering discussion may commence after the Type B meeting and with commencing preparation of the BLA. The strong balance sheet and Ryoncil sales put MSB in a strong position for partnering discussions

CLBP enrolment for P3 confirmatory study continues. No numbers quoted

BP valuation remains at $3.40

*** I can't help being enthused by the term "path to market". The Type B meeting is about getting this stuff across the counter.